Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 27:18:93-112.
doi: 10.2147/TACG.S518467. eCollection 2025.

A Systematic Review of SNPs Screening for Platinum-Related Pharmacodynamics and Pharmacokinetics Genes in Non-Small Cell Lung Cancer for Precision Medicine

Nadiya Nurul Afifah  1   2 , Annisa Lazuardi Larasati  3 , Indra Wijaya  4 , Neily Zakiyah  5   6 , Ruri Intania  7 , Hideru Obinata  8 , Melisa Intan Barliana  1   6
Affiliations
Review

A Systematic Review of SNPs Screening for Platinum-Related Pharmacodynamics and Pharmacokinetics Genes in Non-Small Cell Lung Cancer for Precision Medicine

Nadiya Nurul Afifah et al. Appl Clin Genet. .

Abstract

Introduction: Traditional treatments for non-small cell lung cancer (NSCLC), such as chemotherapy, especially platinum-based regimens, often lack efficacy due to the disease's inherent heterogeneity. Precision medicine in NSCLC recognizes each tumor's unique genetic profile. Alterations in the pharmacokinetics and pharmacodynamics of platinum-based therapies significantly influence their clinical outcomes. Previous research has predominantly focused on genetic polymorphisms in genes like Glutathione S-transferase Pi 1 (GSTP1), ATP Binding Cassette subfamily C member 2 (ABCC2), Excision repair cross-complementation group 1 and 2 (ERCC1, and/ ERCC2), which play crucial roles in detoxification, drug transportation, and Nucleotide Excision Repair (NER). However, findings have shown considerable variability.

Methods: The analysis followed the PRISMA and STROPS Guidelines, using specific search terms including NSCLC, Chemotherapy, Polymorphisms, Single Nucleotide Polymorphisms (SNPs), ERCC1, ERCC2, ABCC2, GSTP1, Effectiveness, and Clinical Response. These studies were subjected to full-text screening process.

Results: Initial screening of 370 studies, comprising 275 from PubMed and 95 from EBSCO, identified 53 relevant ones, excluding those such as reviews, non-English studies, and meta-analyses. Among the genetic variants studied (ERCC1 rs11615, ERCC2 rs13181, ABCC2 rs717620, GSTP1 rs1695), GSTP1 rs1695 emerged as particularly promising, with 11 studies indicating a significant association with improved survival outcomes.

Conclusion: The integration of SNP profiling into clinical decision-making processes holds substantial potential for enhancing the personalization of NSCLC treatment strategies, thereby improving patient outcomes.

Keywords: ABCC2; ERCC1; ERCC2; GSTP1; NSCLC; SNPs; chemotherapy; polymorphisms.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Research Flowchart.
Figure 2
Figure 2
Single Nucleotide Polymorphism Screening Implication on Non-Small Cell Lung Cancer.
Figure 3
Figure 3
Single Nucleotide Excision Repair on ERCC1 and ERCC2.
Figure 4
Figure 4
Single Nucleotide Excision on GSTP1 and ABCC2.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. 2015;12(9):511–526. doi: 10.1038/nrclinonc.2015.90 - DOI - PubMed
    1. Cagle PT, Allen TC, Olsen RJ. Lung cancer biomarkers: present status and future developments. Arch Pathol Lab Med. 2013;137(9):1191–1198. doi: 10.5858/arpa.2013-0319-CR - DOI - PubMed
    1. Huang Y, Liu L, Cai J, et al. The efficacy and response predictors of platinum-based neoadjuvant chemotherapy in locally advanced cervical cancer. Cancer Manag Res. 2020;12:10469–10477. doi: 10.2147/CMAR.S270258 - DOI - PMC - PubMed
    1. Wang Y, Liu ZD, Zhao LM, et al. Individualized treatment of NSCLC: from research to clinical practice. Neoplasma. 2013;60(5):538–545. doi: 10.4149/neo_2013_070 - DOI - PubMed
    1. Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36. doi: 10.1016/j.phrs.2016.01.001 - DOI - PubMed

LinkOut - more resources